The company claims that once developed and approved, ITCA 650 would be the first and only once-yearly injection-free GLP-1 therapy for the treatment of Type 2 diabetes that would help in glycemic control, weight loss and better tolerability.
Under the collaboration, Quintiles will support the development of ITCA 650 by its Capital Solutions group providing a combination of equity, product, and operational investments.
Intarcia Therapeutics executive chairman Kurt Graves said the deal would enforce their company besides accelerating the time-to-market for their injection-free GLP-1 therapy.
"Quintiles’ commitment and intellectual contributions in crafting this development alliance, plus their strategic investments in Intarcia, reflect our vision for ITCA 650 to reshape the way Type 2 diabetes is treated and to deliver significant treatment outcome advantages to patients, payors and providers," Graves added.
Â